Alternate dosing regimens of brentuximab vedotin for CD30+ cutaneous T-cell lymphoma

Br J Dermatol. 2018 Jan;178(1):302-303. doi: 10.1111/bjd.15970. Epub 2018 Jan 10.

Authors

D J Lewis^{1

2}, Y H Kim³, M Duvic²

Affiliations

¹ School of Medicine, Baylor College of Medicine, Houston, TX, U.S.A.
² Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, TX, U.S.A.
³ Department of Dermatology, Stanford University School of Medicine, Stanford, CA, U.S.A.

PMID: 28889405
DOI: 10.1111/bjd.15970

No abstract available

Publication types

Letter
Comment

MeSH terms

Brentuximab Vedotin
Humans
Immunoconjugates*
Ki-1 Antigen*
Lymphoma, T-Cell, Cutaneous

Substances

Immunoconjugates
Ki-1 Antigen
Brentuximab Vedotin